Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson’s Disease

Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort

(2014) Tessandra Stewart et al.   AMERICAN JOURNAL OF PATHOLOGY

Cognitive executive impairment and dopaminergic deficits inde novoParkinson's disease

(2014) Françoise J. Siepel et al.   MOVEMENT DISORDERS

Initial cognitive decline is associated with cortical thinning in early Parkinson disease

(2014) J. B. Pereira et al.   NEUROLOGY

CSF A 42 predicts early-onset dementia in Parkinson disease

(2014) G. Alves et al.   NEUROLOGY

CSF biomarkers and clinical progression of Parkinson disease

(2014) S. Hall et al.   NEUROLOGY

Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease

(2014) Nagaendran Kandiah et al.   PARKINSONISM & RELATED DISORDERS

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

(2014) Lucilla Parnetti et al.   Frontiers in Aging Neuroscience

Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly

(2013) Lidia Glodzik   Frontiers in Bioscience-Landmark

The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia

(2013) Yaroslau Compta et al.   Neurodegenerative Diseases

Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study

(2013) A. J. Yarnall et al.   NEUROLOGY

Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study

(2013) Yaroslau Compta et al.   PARKINSONISM & RELATED DISORDERS

Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging

(2012) David R. Roalf et al.   Alzheimers & Dementia

Neuropathologic substrates of Parkinson disease dementia

(2012) David J. Irwin et al.   ANNALS OF NEUROLOGY

Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment

(2012) Per Svenningsson et al.   LANCET NEUROLOGY

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

(2012) Irene Litvan et al.   MOVEMENT DISORDERS

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

(2012) S. N. Gomperts et al.   NEUROLOGY

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

CSF amyloid-  and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

(2010) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease

(2010) Angie A Kehagia et al.   LANCET NEUROLOGY

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease

(2010) James B. Leverenz et al.   PARKINSONISM & RELATED DISORDERS

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

(2009) Caroline H. Williams-Gray et al.   BRAIN

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

(2009) Yaroslau Compta et al.   MOVEMENT DISORDERS